Cravens & Co Advisors Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PGIM Ultra Short Bond ETF
PULS
|
+$7.49M |
| 2 |
UnitedHealth
UNH
|
+$849K |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$433K |
| 4 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$424K |
| 5 |
NVO
Novo Nordisk
NVO
|
+$424K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SmartFinancial
SMBK
|
+$2.12M |
| 2 |
iShares Treasury Floating Rate Bond ETF
TFLO
|
+$611K |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$607K |
| 4 |
Sea Limited
SE
|
+$475K |
| 5 |
TSMC
TSM
|
+$447K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 9.21% |
| 2 | Technology | 6.58% |
| 3 | Healthcare | 4.79% |
| 4 | Communication Services | 3.75% |
| 5 | Consumer Discretionary | 3.69% |
Similar funds
Cravens & Co Advisors's Q3 2025 Portfolio in Review
As of Q3 2025, Cravens & Co Advisors held 59 positions worth $146M, up 9.3% from $134M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Cravens & Co Advisors deployed $6.53M of net new capital in Q3 2025, opening 4 new positions and adding to 22 existing holdings. Its largest new stake was PGIM Ultra Short Bond ETF: 150,697 shares worth $7.51M.
By sector, the portfolio is most concentrated in Financials at 9.2% of assets, down from 11% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was SmartFinancial, an estimated $2.12M trimmed.
- Cravens & Co Advisors's largest Q3 2025 buy was PGIM Ultra Short Bond ETF: 150,697 shares worth $7.51M.
- Cravens & Co Advisors added most to Vertex Pharmaceuticals in Q3 2025, an estimated $433K increase.
- Cravens & Co Advisors's biggest Q3 2025 reduction was SmartFinancial, cutting an estimated $2.12M.
- Cravens & Co Advisors fully exited Altria Group in Q3 2025, selling an estimated $444K.
- Cravens & Co Advisors's ten largest holdings make up 66% of its $146M portfolio in Q3 2025.
- Cravens & Co Advisors opened 4 new positions and closed 1 in Q3 2025.
- Cravens & Co Advisors's portfolio value rose 9.3% quarter-over-quarter to $146M.
Based on Cravens & Co Advisors's 13F filing for Q3 2025, filed 29 Oct 2025.